Advancing Precision Medicine With FGFR Inhibitors in Cholangiocarcinoma: What You Need to Know

Text Registration

Advancing Precision Medicine With FGFR Inhibitors in Cholangiocarcinoma: What You Need to Know

Status

Published

on 14 Apr 2020

Year of Creation

2020

Med-IQ

Registration Number

TX0008866986

on 14 Apr 2020

The U.S. Copyright record (Registration Number: TX0008866986) dated 14 Apr 2020, pertains to an electronic file (eService) titled "Advancing Precision Medicine With FGFR Inhibitors in Cholangiocarcinoma: What You Need to Know " created in 2020. The copyright holder is Med-IQ, known for their creative contributions in text registration. For any inquiries concerning this copyrighted material, kindly reach out to Med-IQ.

Med-IQ

Application Details

Registration Number

TX0008866986

Registration Date

4/14/2020

Year of Creation

2020

Agency Marc Code

DLC-CO

Record Status

New

Corporate Author

Med-IQ

Physical Description

Electronic file (eService)

First Publication Nation

United States

Corporate Authors

Med-IQ

Notes

Rights Note: Susan Dembeck, Med-IQ, 5523 Research Park Dr, Ste 210, Baltimore, MD, 21228, United States, (443) 543-5114, sdembeck@med-iq.com

Statements

Application Title Statement: Advancing Precision Medicine With FGFR Inhibitors in Cholangiocarcinoma: What You Need to Know

Author Statement: Med-IQ employer for hire Citizenship: United States Authorship: text

Notes

Rights Note: Susan Dembeck, Med-IQ, 5523 Research Park Dr, Ste 210, Baltimore, MD, 21228, United States, (443) 543-5114, sdembeck@med-iq.com

Statements

Application Title Statement: Advancing Precision Medicine With FGFR Inhibitors in Cholangiocarcinoma: What You Need to Know

Author Statement: Med-IQ employer for hire Citizenship: United States Authorship: text

Get your copyright registered todayThousands have copyrighted their assets.
What are you waiting for?

Show terms & conditions

Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal advice. Although LegalForce RAPC Worldwide P.C., dba Trademarkia P.C., is a law firm (the “Firm”), your use of this website does not establish an attorney-client relationship with the Firm. Such a relationship can only be established after the Firm decides that it is willing and able to accept the engagement after a conflict check and after a written retainer agreement is agreed upon between you and the Firm. Your use of this website is also subject to our Terms of Use and Privacy Policy. ** The entry level subscription is a bundled price which requires a minimum of two billing cycles, or 6 months.